Total effective vascular compliance in patients with cirrhosis. Effects of propranolol

Journal of Hepatology

Volumn 36, Issue 3, 2002, Pages 356-361

  Andreu, Victoria ^a   Perello, Antonia ^a   Moitinho, Eduardo ^a   Escorsell, Angels ^a   García Pagán, Juan Carlos ^a   Bosch, Jaume ^a   Rodés, Joan ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Cirrhosis; Portal hypertension; Propranolol; Total effective vascular compliance

Indexed keywords

PLACEBO; PROPRANOLOL;

ADULT; ARTICLE; BLOOD VESSEL COMPLIANCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEART RIGHT ATRIUM PRESSURE; HEMODYNAMICS; HUMAN; LIVER CIRRHOSIS; LIVER DISEASE; MALE; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL;

COMPLIANCE; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROPRANOLOL; VASODILATOR AGENTS;

EID: 0036192023     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(01)00300-2     Document Type: Article

References (46)

1. Nitric oxide and endothelin as potential targets for the treatment of portal hypertension
2. Pathophysiology of portal hypertension and its complications
3. Pathophysiology of portal hypertension
4. Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis
5. Reduced central blood volume in cirrhosis
6. Clinical pharmacology, physiology and pathophysiology of superficial veins
7. Total effective vascular compliance in patients with cirrhosis: A study of the response to acute blood volume expansion
8. Role of central blood volume in the development of sodium retention in portal hypertensive rats
9. Favorable effects of total paracentesis on splachinc hemodynamics in cirrhotic patients with tense ascites
10. Hemodynamic effects of blood volume restitution following a hemorrhage in rats with portal hypertension due to cirrhosis of the liver: Influence of the extent of portal-systemic shunting
11. Pulmonary vascular disorders in portal hypertension
12. Common bile duct ligation in the rat: A model of intrapulmonary vasodilatation and hepatopulmonary syndrome
13. Increased portal venous resistance hinders portal pressure reduction during the administration of β-adrenergic blocking agents in a portal hypertensive model
14. Complications of cirrhosis. I. Portal hypertension
15. Effects of alpha-adrenergic stimulation and beta-adrenergic blockade on azygos blood flow and splanchnic haemodynamics in patients with cirrhosis
16. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of the first variceal hemorrhage
17. Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrato to propranolol administration in patients with cirrhosis
18. Transection of the oesophagus for bleeding oesophageal varices
19. Thermodilution cardiac output determination with a single flow-directed catheter
20. Effective compliance of the total vascular bed and the intrathoracic compartment derived from changes in central venous pressure induced by volume changes in man
21. Total effective compliance, cardiac output and fluid volumes in essential hypertension
22. Wedged and free hepatic venous pressure measured with a balloon catheter
23. Evidence against a role for inducible nitric oxide synthase in the hyperdynamic circulation of portal hypertensive rats
24. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition
25. Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis
26. Role of nitric oxide in the in vitro splanchnic vascular hypo reactivity in ascitic cirrhotic rats
27. Effects of prostaglandin inhibition on systemic and hepatic hemodynamics in patients with cirrhosis of the liver
28. Acute and chronic cyclooxigenase blockade in portal-hypertensive rats: Influence on nitric oxide biosynthesis
29. Atrial natriuretic peptide antagonizes endothelin induced calcium increase and cell contraction in cultured human hepatic stellate cells
30. Glucagon hinders the effects of somatostatin on portal hypertension. A study in rats with partial portal vein ligation
31. Effects of somatostatin on splanchnic hemodynamics and plasma glucagon in portal hypertensive rats
32. Increased adrenomedullin levels in cirrhosis: Relationship with hemodynamic abnormalities and vasoconstrictor systems
33. Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis
34. Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome
35. The sympathetic nervous system in liver disease
36. Decreased systemic vascular sensitivity to norepinephrine in portal hypertensive rats: Role of hyperglucagonism
37. Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis
38. Chronic blockade of endothelin receptors in cirrhotic rats: Hepatic and hemodynamic effects
39. Plasma endothelin immunoreactivity in live disease and the hepatorenal syndrome
40. Hypersensitivity of mesenteric veins to 5-hydroxitryptamine and ketanserin-induced reduction of portal pressure in portal hypertensive rats
41. 2-adrenoceptor relaxation is impaired in mesenteric veins from portal-hypertensive rats
42. Pharmacology of portal-systemic collaterals in portal hypertensive rats: Role of endothelium
43. Carvedilol, a new non-selective beta-blocker with intrinsic alpha 1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis
44. Beta-blockers of the third generation inhibit endothelin-1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells
45. Reversal of adrenaline-induced increase in azygos blood flow in patients with cirrhosis receiving propranolol
46. Effects of propranolol on azygos venous blood flow and hepatic and systemic hemodynamics in cirrhosis